Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension of Voxelotor in Sickle Cell Disease
PACTR202209867711506Phase 3Recruiting
- Sponsor
- Global Blood Therapeutics
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of voxelotor in sickle cell disease (SCD), sponsored by Global Blood Therapeutics. Primary endpoints: Treatment-emergent adverse events and serious adverse events and Sickle cell disease-related complications. Started Dec 2022; status: recruiting.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202209867711506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202209867711506.